Compare LOAN & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOAN | NEPH |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 40.1M |
| IPO Year | 1999 | 2004 |
| Metric | LOAN | NEPH |
|---|---|---|
| Price | $4.44 | $3.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 16.5K | 11.3K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ 1000.00 |
| EPS | ★ 0.11 | 0.01 |
| Revenue | $8,666,307.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ $40.18 | $326.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $4.13 | $2.66 |
| 52 Week High | $5.85 | $6.42 |
| Indicator | LOAN | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 46.22 |
| Support Level | $4.41 | $2.77 |
| Resistance Level | $4.48 | $3.79 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 83.91 | 19.72 |
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.